Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,185 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07168499Recruiting
Diet, stress, and advanced therapy for Crohn's and colitis
This study tests whether adding a diet and stress management program to standard advanced therapy helps people with active Crohn's disease or ulcerative colitis feel better. It combines lifestyle changes with new medications to improve treatment outcomes.
Boston, MassachusettsAges 18 years+ - NCT07172386RecruitingPhase 2
Pre-surgery treatment for advanced kidney cancer
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07174947RecruitingPhase 2
Fluoxetine plus immunotherapy for advanced liver cancer with depression
This study tests whether adding the antidepressant fluoxetine (Prozac) to standard immunotherapy can help treat advanced liver or bile duct cancer in people who also have depression or anxiety. You must not have received any prior cancer treatment and be ready to start immunotherapy as your first therapy.
Wenzhou, ZhejiangAges 18–80 - NCT07177794RecruitingPhase 3
Toripalimab and capecitabine after chemoradiotherapy for esophageal cancer
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07178054Recruiting
Measuring daily energy use in healthy Chinese adults
This study measures how much energy healthy people across China use each day by using a special water test. It helps researchers understand normal energy needs for different populations.
Chongqing, Chongqing MunicipalityAges 7–60 - NCT07183319RecruitingPhase 2
ctDNA test in advanced bladder cancer
This trial studies how a blood test that looks for tumor DNA (ctDNA) can help guide treatment in people with advanced bladder cancer that cannot be removed by surgery or has spread. It aims to see if the test results can help doctors choose the best therapy.
Oklahoma City, OklahomaAges 18 years+ - NCT07186010Recruiting
Immune therapy biomarkers in advanced liver cancer
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Seoul, Song-paAges 19 years+ - NCT07186218Recruiting
Symptom monitoring with feedback for advanced kidney disease
This study tests a symptom-monitoring system with feedback for people with advanced chronic kidney disease (CKD). The goal is to help manage symptoms and improve quality of life without needing dialysis or a transplant right away.
Boston, MassachusettsAges 18 years+ - NCT07186725Recruiting
Home sleep monitor for obstructive sleep apnea
This trial tests a new home-based sleep monitor that goes under your mattress. It may help people with obstructive sleep apnea who are using a mouthpiece (MAD) as treatment.
Lexington, KentuckyAges 18–80 - NCT07192185RecruitingPhase 2
Chemo plus immunotherapy for advanced liver cancer after first treatment fails
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Guangzhou, GuangdongAges 18–75 - NCT07193550RecruitingPhase 2
Testing Zanzalintinib for Advanced Bone Sarcomas
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
Houston, TexasAges 18 years+ - NCT07193654RecruitingPhase 2
Combined stupp therapy and spinal chemo for advanced glioblastoma
This trial tests adding a chemotherapy drug (thiotepa) directly into the spinal fluid for people with a newly diagnosed glioblastoma that has spread to the brain's lining or ventricles. It aims to see if this extra treatment can help control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Duarte, CaliforniaAges 18 years+ - NCT07199959Recruiting
Study on why entrectinib stops working in ROS1 lung cancer
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07205731RecruitingPhase 2
Tislelizumab for older adults with advanced esophageal cancer
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Annecy, Epagny Metz-TessyAges 70 years+ - NCT07206498RecruitingPhase 1/Phase 2
Study of WSD0922-FU with Osimertinib for advanced NSCLC
This trial tests a new combination treatment (WSD0922-FU plus osimertinib) for people with advanced non-small cell lung cancer (NSCLC) that has a specific EGFR mutation. The goal is to see if the combination is safe and effective.
ShanghaiAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT07215182RecruitingPhase 2
New PET scan method for advanced melanoma
This trial tests a new type of PET scan that may find cancer more clearly and quickly than current scans. It's for people with advanced melanoma that has spread and cannot be removed by surgery.
Herlev, Capital RegionAges 18 years+ - NCT07217821Recruiting
Music and imagery for chronic pain
This study tests a step-by-step approach using music and guided imagery to help people with long-term muscle or joint pain. It's done from home using a device, so you don't need to travel.
Indianapolis, IndianaAges 18 years+ - NCT07222683Recruiting
How kidney transplant affects heart blood vessel health
This study looks at how receiving a kidney transplant changes the health of small blood vessels in the heart. It may help people with advanced kidney disease understand the benefits of transplant on their heart health.
Boston, MassachusettsAges 18 years+ - NCT07234487RecruitingPhase 2
Comparing two drug combos for advanced Hodgkin lymphoma
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
MoscowAges 18–60 - NCT07237594RecruitingPhase 1
IL-17 blocker to prevent immunotherapy side effects
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
Durham, North CarolinaAges 18 years+ - NCT07240363Recruiting
Surgery or fertility treatment first for advanced endometriosis
This trial compares starting with surgery versus starting with fertility treatment (like IVF) for people with advanced endometriosis who may want to have children. The goal is to see which approach first leads to better outcomes.
Stockholm, Stockholm CountyAges 18–38 - NCT07243626RecruitingPhase 2
Envafolimab plus chemo for advanced soft tissue sarcoma
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
Hanzhong, ZhejiangAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,185 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.